Mesalamine
Last Updated: 09/19/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5572 publications
Mesalazine enteric-coated tablets combined with retention enema for symptom alleviation in mild to moderate E2-type active ulcerative colitis: A retrospective comparative cohort study.
Journal: Pakistan journal of pharmaceutical sciences
Published: September 08, 2026
Electrochemical sensing of 5-aminosalicylic acid via DES-based molecularly imprinted polymers/rGO: experimental and theoretical insights.
Journal: The Analyst
Published: August 27, 2026
Rosuvastatin and engeletin ameliorate acetic acid-induced ulcerative colitis through modulation of TXNIP/NLRP3-related inflammatory signaling pathway.
Journal: Immunopharmacology and immunotoxicology
Published: August 24, 2026
Development of discriminatory and biopredictive bicarbonate buffer-based dissolution method to screen delayed release formulations.
Journal: Drug development and industrial pharmacy
Published: August 18, 2026
Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations.
Journal: Drug development and industrial pharmacy
Published: August 12, 2026
Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group.
Journal: Journal of Crohn's & colitis
Published: August 09, 2026
Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis.
Journal: The Cochrane database of systematic reviews
Published: July 27, 2026
A Case Report of Mesalazine-Induced Pulmonary Injury in a Patient With Ulcerative Colitis.
Journal: HCA healthcare journal of medicine
Published: July 25, 2026
Discovery of a gut-restricted LANCL2 agonist for the treatment of inflammatory bowel disease.
Journal: European journal of medicinal chemistry
Published: July 22, 2026
Exploring the potential of direct electricity-driven synthesis of mesalazine-tetramer and olsalazine, an anti-inflammatory drug.
Journal: RSC advances
Published: July 17, 2026
Mesalazine Nonadherence in Mild-to-Moderate Ulcerative Colitis: Barriers in a Moroccan Cohort.
Journal: Cureus
Published: July 14, 2026
Clinical characteristics, treatment and prognosis of ixekizumab-induced inflammatory bowel disease.
Journal: Immunopharmacology and immunotoxicology
Published: July 09, 2026
Last Updated: 09/19/2026